

NOTES

Cephalosporin Podand Derivatives

ÁRPÁD KOVÁCS-KULYASSA^{††},

PÁL HERCZEGH* and FERENC J. SZTARICSKAI*

Research Group for Chemistry of Antibiotics of the Hungarian
Academy of Sciences, University of Debrecen,
H-4010 Debrecen PoBox 70, Hungary

PÁL SZABÓ

Institute of Chemistry, Hungarian Academy of Sciences;
H-1525 Budapest, PoBox 17, Hungary

(Received for publication June 14, 2000)

In recent years the design and preparation of dendrimers and another multivalent molecules have emerged intensively studied subjects in organic synthesis¹. Biologically important substances, such as carbohydrates²⁻⁷, amino acids⁸ often serve as the functional groups of these types of oligomers.

In many cases, related multivalent compounds possess remarkable biological effects. As an example, the so-called cluster effect in the case of the carbohydrate-containing substances is manifested in the enhanced affinity of the dendrimers towards another biomolecules due to weak, non-bonding interactions⁹.

In the field of antibiotics, covalent oligomers or polymers have only been synthesized from vancomycin¹⁰⁻¹², and the complex-forming, and antibacterial properties of the derivatives obtained were found to be better than that of the parent, monomeric antibiotic¹³.

Till now, no multivalent derivatives of the β -lactam antibiotics have been synthesized. In continuation of our work in the synthesis of podand molecules⁶, the present paper describes the preparation of certain podand-type trimers of cephalosporin antibiotics (Scheme 1).

As the central block of the target trimers the tricarboxylic acid **3** was employed, which was obtained by the alkylation of phloroglucinol (**1**) with methyl bromoacetate and subsequent alkaline hydrolysis. The *tert*-butyl esters of 7-aminocephalosporanic acid (**5**)¹⁴ and 7-

aminodeacetoxycephalosporanic acid (**6**)¹⁴ were acylated with the acid chloride **4** derived from **3** to obtain the trimers **9** and **11**, respectively. Removal of the *tert*-butyl protecting group of these products upon hydrolysis with trifluoroacetic acid followed by potassium salt formation furnished the target podands **10** and **12**.

It is well-known from the literature that certain cephalosporin sulfones possess β -lactamase enzyme inhibitory properties¹⁵, and therefore, we decided to synthesize structurally related sulphone-trimers, as well. Thus, the *tert*-butyl ester of 7-aminocephalosporanic acid sulphone (**7**)¹⁶ and the corresponding deacetoxy derivative **8** were acylated with the acid chloride **4** to give **13** and **15**. Subsequent removal of the ester protecting group by hydrolysis with trifluoroacetic acid then furnished the desired trimeric cephalosporin sulphones **14** and **16**.

The antibacterial activity of the cephalosporin trimers prepared was compared to that of a cefuroxime reference sample by using the agar-dilution method (Nutrient Broth). Against *Staphylococcus aureus* ATCC25923, cefuroxime showed a MIC of 1.5 μ g/ml, but compounds **10** and **12** were active only in 12.5 and 50 μ g/ml concentration, respectively. The podand **10** was considerably more active (MIC 3.12 μ g/ml) against *Streptococcus faecalis* (OKI[†])80171 than cefuroxime (MIC 12.5 μ g/ml), while the antibacterial effect of cefuroxime and of the trimer **12** was in the same range against this microorganism. The synthesized trimers were practically inactive against *Bacillus subtilis* ATCC6633, *Escherichia coli* (OKI)35034, *Proteus vulgaris* (OKI)60002 and *Pseudomonas aeruginosa* ATCC27853. In addition, the trimeric cephalosporin sulphone derivatives **13** and **15** did not show inhibitory effect (in 50 μ mole concentration) on the β -lactamase enzymes produced by the strains *B. cereus*, *E. cloacae*, *E. coli*, *P. vulgaris* and *P. aeruginosa*.

The expected cluster effect of our cephalosporin podands unfortunately could not be detected in their biological tests. Preparation of similar podands of other antibiotics is under study in our laboratory.

Dedicated to the memory of Sir EDWARD ABRAHAM.

[†] Hungarian National Institute of Health (Budapest).

^{††} Present address: Laboratoire de Chimie Thérapeutique, Faculté de Pharmacie. Université de Reims.

Scheme 1. Synthesis of cephalosporin podand derivatives.




Table 1. ^1H NMR data of new compounds.

Compound (solvent)	δ_{H}								
	2	6	7	9	R''	R'	11	13	16
2 (CDCl ₃)						3.83 (s, 3H, OMe)		4.59 (s, 2H)	6.14 (s, 1H)
3 (D ₂ O)								4.40 (s, 2H)	6.09 (s, 1H)
9 (CDCl ₃)	3.42; 3.48 (ABq, 2H)	5.02 (d, 1H)	5.93 (dd, 1H)	4.81; 5.1 (ABq, 2H)	1.55 (s, 9H)	2.10 (s, 3H, OAc)	7.22 (d, 1H)	4.55 (s, 2H)	6.18 (s, 1H)
11 (CDCl ₃)	3.22; 3.51 (ABq, 2H)	5.01 (d, 1H)	5.87 (dd, 1H)	2.11 (s, 3H)	1.54 (s, 9H)		7.32 (d, 1H)	4.55 (s, 2H)	6.17 (s, 1H)
13 (CDCl ₃)	3.82; 3.94 (ABq, 2H)	4.86 (d, 1H)	6.13 (dd, 1H)	4.74; 5.14 (ABq, 2H)	1.54 (s, 9H)	2.09 (s, 3H, OAc)	7.88 (d, 1H)	4.53; 4.60 (ABq, 2H)	6.17 (s, 1H)
15 (CDCl ₃)	3.67; 3.82 (ABq, 2H)	4.80 (d, 1H)	6.06 (dd, 1H)	2.07 (s, 3H)	1.53 (s, 9H)		7.90 (d, 1H)	4.54; 4.66 (ABq, 2H)	6.19 (s, 1H)
10 (D ₂ O)	3.31; 3.58 (ABq, 2H)	5.06 (d, 1H)	5.66 (dd, 1H)	4.65; 4.84 (ABq, 2H)		2.05 (s, 3H, OAc)		4.7 (s, 2H)	6.28 (s, 1H)
12 (D ₂ O)	3.14; 3.50 (ABq, 2H)	5.02 (d, 1H)	5.57 (dd, 1H)	1.85 (s, 3H)				4.68 (s, 2H)	6.25 (s, 1H)
8 (CDCl ₃)	3.43; 3.87 (ABq, 2H)	4.71 (d, 1H)	4.87 (d, 1H)	2.07 (s, 3H)	1.55 (s, 9H)		2.15 (m, 2H)		
14 (D ₂ O)	3.94; 4.24 (ABq, 2H)	5.31 (d, 1H)	6.00 (d, 1H)	4.70; 4.92 (ABq, 2H)		2.10 (s, 3H, OAc)		4.71 (s, 2H)	6.22 (s, 1H)
16 (D ₂ O)	3.77; 4.12 (ABq, 2H)	5.21 (d, 1H)	5.91 (d, 1H)	1.87 (s, 3H)				4.64 (s, 2H)	6.14 (s, 1H)

Experimental

Solvents were distilled before use. Organic extracts were dried over magnesium sulphate. Solutions were concentrated at 35~40°C (bath) at *ca.* 17 mmHg. Melting points were determined in capillary tubes and are uncorrected. For thin layer chromatography precoated aluminum-backed plates (Silica gel 60 F₂₅₄, Merck, layer thickness: 0.2 mm) were used. The spots were visualized by spraying with 7% ammonium molybdate in 5% sulfuric acid and heating. Preparative TLC was carried out on Merck silica gel 60 F₂₅₄ plates, layer thickness 0.25 and 0.5 mm. IR spectra (KBr discs) were recorded on a Perkin-Elmer 16 PC FT-IR spectrophotometer. Specific rotations were measured on a Perkin-Elmer 141 MC polarimeter at room temperature. ^1H NMR spectra: Bruker WP 200 SY (200 MHz) and Bruker AM 360 (360 MHz) instruments; tetramethylsilane as internal standard. ^{13}C NMR spectra were recorded on Bruker WP 200 SY (50 MHz) and on

Bruker AM 360 (90 MHz) instruments (Table 1). Electrospray (ESP) mass spectrometric measurements (positive and negative ion detections) were run on a FINNIGAN TSQ 7000 triple quadrupole mass spectrometer equipped with API source; samples were introduced into 50% methanol solutions containing 0.1% acetic acid or 0.1% ammonium acetate. All compounds gave satisfactory elemental analysis data.

(3,5-Bis-methoxycarbonyl-methoxy-phenoxy)acetic Acid Methyl Ester (2)

Phloroglucinol (2.00 g, 15.9 mmol) was dissolved in the suspension of abs. acetone (100 ml) and potassium carbonate (10.0 g). Methyl bromoacetate (6.80 ml, 71.4 mmol) was added to the well-stirred slurry and the mixture was refluxed for 12 hours. The solid was filtered off, washed with dichloromethane and the organic solvents were evaporated. The residue was dissolved in dichloromethane (100 ml), extracted with 10% NaHSO₄

solution and brine, dried and evaporated. The product crystallized by adding abs. ether, 3.22 g (59%), mp: 131~132°C; FT-IR (KBr) 1770 cm^{-1} ; ESP-MS (m/z): 343 ($\text{M}+\text{H}^+$); ^{13}C NMR (50 MHz, CDCl_3) δ : 52.3, 65.2, 95.2, 159.6, 168.9.

(3,5-Bis-carboxymethoxy-phenoxy)acetic Acid (3)

Compound **2** (2.13 g, 6.23 mmol) was dissolved in 10% NaOH solution (15 ml) and warmed at 80°C for 12 hours. After cooling, the clear solution was extracted with ethyl acetate and the aqueous phase was acidified carefully with 10% HCl solution. The precipitate was collected by filtration, washed with cold water and dried in a desiccator, 1.77 g of white powder (95%), mp 304~305°C (dec.); FT-IR (KBr) 1740 cm^{-1} ; ESP-MS (m/z): 301 ($\text{M}+\text{H}^+$); ^{13}C NMR (50 MHz, $\text{D}_2\text{O}+\text{K}_2\text{CO}_3$) δ : 67.5, 95.1, 160.3, 167.6.

tert-Butyl 7-Amino-deacetoxycephalosporanoate 1,1-Dioxide (8, R=H)

The reaction was carried out starting from **6** as it is described for *tert*-butyl 7-amino-cephalosporanoate 1,1-dioxide (**7**). Yield 77%; FT-IR (KBr) ν_{max} 3414, 1754, 1712, 1652 cm^{-1} ; $[\alpha]_{\text{D}}^{23}+14.7$ (c 1.11, CHCl_3); ESP-MS m/z : 303 ($\text{M}+\text{H}^+$), 301 ($\text{M}-\text{H}^-$).

General Procedure for the Acylation of β -Lactam Esters

The suspension of acid **3** (0.20 mmol) in SOCl_2 (2 ml) was refluxed for 2 hours under Ar. The resulting clear mixture was evaporated and co-evaporated with abs. benzene (3 \times 5 ml). The crude acyl chloride **4** was dissolved in abs. dichloromethane (2 ml) and added dropwise to the cooled solution of a β -lactam ester (0.60 mmol) in dichloromethane (2 ml) and abs. pyridine (1.20 mmol). The stirred mixture was allowed to warm up to r.t. (2 hours), diluted with dichloromethane, extracted with 10% NaHSO_4 , sat. NaHCO_3 solutions and brine, dried and purified by column chromatography or preparative TLC.

tert-Butyl 7-(3,5-Bis-(((6*R*,7*R*)3-acetoxymethyl-4-*tert*-butoxycarbonyl-cephem-7-ylcarbamoyle)-methoxy))-phenoxyacetamido Acetoxycephalosporanoate (9)

Starting from **5**, yield 50%, mp 166~167°C (dec.); FT-IR (KBr) ν_{max} 1786, 1728, 1602, 1522 cm^{-1} ; $[\alpha]_{\text{D}}^{23}+26.1$ (c 1.89, CHCl_3); ESP-MS: m/z 1248 ($\text{M}+\text{NH}_4^+$).

tert-Butyl 7-(3,5-Bis-(((6*R*,7*R*)4-*tert*-butoxycarbonyl-3-methyl-cephem-7-ylcarbamoyle)-methoxy))-phenoxyacetamido Deacetoxycephalosporanoate (11)

Starting from **6** ($\text{R}=\text{H}$)¹⁾, yield 49%; mp 195~196°C (dec.); FT-IR (KBr) ν_{max} 1782, 1716, 1602, 1522 cm^{-1} ;

$[\alpha]_{\text{D}}^{23}+71.8$ (c 1.02, CHCl_3); ESP-MS m/z : 1074 ($\text{M}+\text{NH}_4^+$), 1079 ($\text{M}+\text{Na}^+$), 1095 ($\text{M}+\text{K}^+$).

tert-Butyl 7-(3,5-Bis-(((6*R*,7*R*)3-acetoxymethyl-4-*tert*-butoxycarbonyl-1,1-dioxo-cephem-7-ylcarbamoyle)-methoxy))-phenoxyacetamido Acetoxycephalosporanoate 1,1-Dioxide (13)

Starting from **7**, yield 47%, mp 169~170°C (dec.); FT-IR (KBr) ν_{max} 1806, 1724, 1608, 1522 cm^{-1} ; $[\alpha]_{\text{D}}^{23}-39.0$ (c 1.29, CHCl_3); ESP-MS: m/z 1344 ($\text{M}+\text{NH}_4^+$).

tert-Butyl 7-(3,5-Bis-(((6*R*,7*R*)4-*tert*-butoxycarbonyl-1,1-dioxo-3-methyl-cephem-7-ylcarbamoyle)-methoxy))-phenoxyacetamido Deacetoxycephalosporanoate 1,1-Dioxide (15)

Starting from **8** ($\text{R}=\text{H}$), yield 57%, mp 191~192°C (dec.); FT-IR (KBr) ν_{max} 1796, 1716, 1608, 1522 cm^{-1} ; $[\alpha]_{\text{D}}^{23}+26.1$ (c 0.57, CHCl_3); ESP-MS m/z : 1170 ($\text{M}+\text{NH}_4^+$), 1175 ($\text{M}+\text{Na}^+$), 1191 ($\text{M}+\text{K}^+$).

General Procedure for the Synthesis of the Potassium Cephalosporanoate Podands

tert-Butyl cephalosporanoate podand (0.10 mmol) was dissolved in 30% trifluoroacetic acid in dichloromethane (9 ml) and stirred at r.t. for 1.5 hours. The solvents were evaporated and co-evaporated with abs. benzene (3 \times 5 ml). The residue was suspended in a solution of potassium α -ethylcaproate (2 equiv.) in abs. ether (10 ml) and stirred for 16 hours. The ethereal phase was decanted, the remaining solid was decanted with abs. ether (3 \times 5 ml), dissolved in distilled water (10 ml), and filtered through a celite pad. Lyophilization resulted in hygroscopic flaky solids.

7-(3,5-Bis-(((6*R*,7*R*)3-acetoxymethyl-4-carboxy-cephem-7-ylcarbamoyle)-methoxy))-phenoxyacetamido Acetoxycephalosporanoic Acid Tripotassium salt (10)

Starting from **9**, yield 72%; FT-IR (KBr) ν_{max} 1762, 1684, 1608, 1558, 1540 cm^{-1} ; $[\alpha]_{\text{D}}^{23}+77.9$ (c 0.97, H_2O); ESP-MS: m/z 1061 ($\text{M}-\text{H}^-$).

7-(3,5-Bis-(((6*R*,7*R*)4-carboxy-3-methyl-cephem-7-ylcarbamoyle)-methoxy))-phenoxyacetamido Deacetoxycephalosporanoic Acid Tripotassium Salt (12)

Starting from compound **11**, yield: 82%; FT-IR (KBr) ν_{max} 1750, 1684, 1602, 1558, 1540 cm^{-1} ; $[\alpha]_{\text{D}}^{23}+130.2$ (c 0.94, H_2O); ESP-MS m/z : 906 ($\text{M}+\text{NH}_4^+$), 911 ($\text{M}+\text{Na}^+$), 887 ($\text{M}-\text{H}^-$).

7-(3,5-Bis-(((6*R*,7*R*)3-acetoxymethyl-4-carboxy-1,1-dioxo-cephem-7-ylcarbamoyl)-methoxy))-phenoxyacetamido Acetoxycephalosporanoic Acid 1,1-Dioxide Tripotassium Salt (14)

Starting from **13**, yield 78%; FT-IR (KBr) ν_{\max} 1784, 1684, 1616, 1540, 1522 cm^{-1} ; $[\alpha]_{\text{D}}^{23} + 24.7$ (c 0.85, H_2O); ESP-MS: m/z 1157 ($\text{M}-\text{H}$)⁻.

7-(3,5-Bis-(((6*R*,7*R*)4-carboxy-1,1-dioxo-3-methyl-cephem-7-ylcarbamoyl)-methoxy))-phenoxyacetamido deacetoxycephalosporanoic Acid 1,1-Dioxide Tripotassium Salt (16)

Starting from **15**, yield 81%; FT-IR (KBr) ν_{\max} 1772, 1684, 1608, 1558, 1540 cm^{-1} ; $[\alpha]_{\text{D}}^{23} + 46.2$ (c 1.23, H_2O); ESP-MS m/z : 983 ($\text{M}-\text{H}$)⁻, 491 ($\text{M}-\text{H}$)²⁻.

Acknowledgements

The authors thank the Hungarian Research Foundation for financial support through grants OTKA T19338, OTKA T30138, OTKA T02975. Thanks are due to Professor F. HERNÁDI and Á. KONCZ for the biological tests and for A. AGÓCS for his help in the preparation of the manuscript.

References

- ISSBERNER, J.; R. MOORS & F. VÖGTLE: Dendrimers: from generation and functional groups to function. *Angew. Chem. Int. Ed. Engl.* 33: 2413~2420, 1994
- ROY, R.; D. ZANINI, S. J. MENNIER & A. ROMANOWSKA: Solid phase synthesis of dendritic sialoside inhibitors of influenza A virus haemagglutinine. *J. Chem. Soc. Chem. Comm.* 1869~1872, 1993
- BINDER, W. H. & W. SCHMIDT: Synthesis of a symmetric multivalent molecule containing four carbohydrate substituents. *Monatsh. Chem.* 126: 923~931, 1995
- GRIENDLEY, T. B. & H. NAMAZI: The regioselective synthesis of non-glycosidically linked oligosaccharides. *Tetrahedron Lett.* 37: 991~994, 1996
- LINDHORST, T. K. & C. KIEBURG: Glycoconjugates of oligovalent amines: synthesis of thiourea-bridged cluster glycosides from glycosyl isothiocyanates. *Angew. Chem. Int. Ed. Engl.* 36: 1953~1956, 1996
- HERCZEGH, P.; Á. KOVÁCS-KULYASSA, GY. ERDŐSI, L. KOVÁCS, T. MENYHÁRT, P. T. SZABÓ & J. KÖRNYEI: Thioglycosidic carbohydrate podands. *Carbohydrate Lett.* 3: 59~64, 1998
- PATCH, R. J.; H. CHEN & C. PANDIT: Multivalent templated saccharides: convenient syntheses of spacer-linked 1,1'-bis and 1,1',1''-tris- β -glycosides by the glycal epoxide glycosylation method. *J. Org. Chem.* 62: 1543~1545, 1997
- SHAO, J. & J. P. TAM: Unprotected peptides as building blocks for the synthesis of peptide dendrimers with oxime, hydrazone and thiazolidine analogs. *J. Am. Chem. Soc.* 117: 3893~3899, 1995
- LEE, Y. C.; R. R. TOWNSEND, M. R. HARDY, J. LÖNGRENN, M. ARNARP, M. HARALDSON & H. LÖNN: Binding of synthetic oligosaccharides to the Gal/GalNAc lectin. Dependence on fine structural features. *J. Biol. Chem.* 258: 199~206, 1983
- WHITESIDES, G. M.; M. MAMMEN & S.-K. CHOI: Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. *Angew. Chem. Int. Ed. Engl.* 37: 2754~2794, 1998
- RAO, J. & G. M. WHITESIDES: Tight binding of a dimeric derivative of vancomycin with dimeric L-Lys-D-Ala-D-Ala. *J. Am. Chem. Soc.* 119: 10286~10290, 1997
- STAROSKE, T. & D. H. WILLIAMS: Synthesis of covalent head-to-tail dimers of vancomycin. *Tetrahedron Lett.* 39: 4917~4920, 1998
- ARIMOTO, H.; K. NISHIMURA, T. KINUMI, I. HAKAGAWA & D. UEMURA: Multivalent polymer of vancomycin enhanced antibacterial activity against VRE. *J. Chem. Soc. Chem. Comm.* 1361~1362, 1999
- GRIGAN, N.; D. MUSEL, G. A. VEINBERG & E. LUKEVICS: Synthesis of *N,O*-disubstituted-3-hydroxymethyl-3-amino cephalosporanic acids. *Synth. Comm.* 1183~1185, 1996
- BUYNAK, J. D.; V. R. DOPPALAPUDI & G. ADAM: The synthesis and evaluation of 3-substituted-7-alkylidenecephalosporin sulfones as β -lactamase inhibitors. *Bioorg. Med. Chem. Letters* 10: 853~857, 2000
- BLACKLOCK, T. J.; J. W. BUTCHER, P. SOHÁR, T. LAMANEC ROTHÁUSER & E. J. GRABOWSKI: A versatile synthesis of 1,1-dioxo 7-substituted cepheems. Preparation of the HLE inhibitor 1,1-dioxo-trans-7-methoxy cephalosporanic acid tert-butyl-ester. *J. Org. Chem.* 54: 3907~3913, 1989